BioMarin Pharma (BMRN) Announces Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $125M
Tweet Send to a Friend
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that it has entered into a definitive agreement to sell the Rare Pediatric ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE